Blue Owl Capital OWL 深 滬
已收盤 05-08 16:00:00 美东时间
10.56
+0.210
+2.03%
華盛通- 最 高10.585
- 今 開10.40
- 成交量 2023.82万股
- 最 低 10.09
- 昨 收 10.35
- 總市值 164.64亿
- 52周最高 20.405
- 市盈率 靜 102.33
- 換手率 1.30%
- 52周最低 7.95
- 委 比 -66.15%
- 總股本 15.59亿
- 歷史最高 25.645
- 量 比 0.47
- 振 幅 4.78%
- 歷史最低 5.625
- 每 手 1
- 風險率 3.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Blackstone, Apollo, And KKR Are Quietly Writing The Same Credit Playbook
Private credit is seen as diversified lending, but major firms are increasingly converging on similar underwriting, deals, and funding models.
05-09 04:51
Blue Owl Preps Credit Secondaries Strategy
Blue Owl Capital (NYSE: OWL) is preparing to launch a credit secondaries strategy and is holding discussions with investors.
05-08 09:24
Blue Owl Capital cuts quarterly dividend 16% amid lower rates, spread compression
Blue Owl Capital (OBDC) declares $0.31/share quarterly dividend, -16.2% decrease from prior dividend of $0.37. Forward yield 10.54% Payable July 15; for shareholders of record June 30; ex-div June 30....
05-07 15:11
CORRECTED-UPDATE 1-Blue Owl private credit fund cuts dividend as borrowing costs rise
CORRECTED-UPDATE 1-Blue Owl private credit fund cuts dividend as borrowing costs rise Corrects headline, paragraphs 1 and 2 to show one fund cut its dividend, not two By Matt Tracy and Isla Binnie May 6 (Reuters) - A Blue Owl Capital OWL.N publicly traded private credit fund cut its dividend on Wedn
05-07 06:31
Blue Owl Capital Q1 Adj. EPS $0.31 Misses $0.35 Estimate, Sales $396.774M Miss $421.882M Estimate
Blue Owl Capital (NYSE:OBDC) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.35 by 11.43 percent. This is a 20.51 percent decrease over earnings of $0.39 per share from
05-07 04:33
私募信贷风暴眼中的Blue Owl(OWL.US)欲蹭上AI风口 Stack亚洲资产蓄力点燃“AI基建叙事”
有媒体援引知情人士透露的消息报道称，由美国最大规模另类资产管理公司之一Blue Owl Capital(OWL.US)持有的大型数据中心公司Stack Inf...
05-06 16:07
Blue Owl旗下数据中心公司Stack据悉考虑出售亚洲业务
据知情人士透露，由Blue Owl Capital拥有的数据中心公司Stack Infrastructure正在考虑包括出售其亚洲业务在内的各种方案。 ...
05-06 11:10
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong Q1 2026 results with global revenue of $205 million, including $195 million from BRIUMVI in the U.S. The company raised its full-year 2026 revenue target to $925 million, with U.S. BRIUMVI net product revenue expected to reach $885-900 million. Q2 2026 BRIUMVI U.S. net product revenue is projected at $220 million. BRIUMVI continues to show strong demand and patient growth, with ongoing clinical developments for sub...
05-06 11:00
SEC Investigates Potential Fraud In Private Credit
U.S. SEC Chairman Paul Atkins says, "Let me be clear that opacity in this space can be an issue. That valuation, transparency and credit quality are key."
05-06 00:46
SA analyst: Broken ceasefire fears rattle markets
U.S. equities closed lower Monday as escalating geopolitical tensions and shifting macro signals weighed on sentiment, reinforcing a cautious tone across global markets. Investors closely monitored de...
05-05 04:19
